P. Riebling

发表

Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

R. Finkel, E. Bertini, S. Peltz, 2017, The Lancet.

Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers.

S. de Vos, T. Kipps, Katti A. Jessen, 2021, NEJM evidence.

Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stress‐Regulated Protein Translation

S. Peltz, Thomas P. Davis, G. Elfring, 2016, Clinical pharmacology in drug development.

Results of North Star Ambulatory Assessments in the Phase 3 Ataluren Confirmatory Trial in Patients with Nonsense Mutation Duchenne Muscular Dystrophy (ACT DMD)

S. Peltz, F. Muntoni, K. Bushby, 2016 .